Low Dose Naltrexone

Low Dose Naltrexone (LDN) refers to naltrexone used at 1-4.5mg daily — a fraction of the standard 50mg dose used for opioid and alcohol addiction. At this low dose, the proposed mechanism and clinical effects are fundamentally different from standard-dose naltrexone.

Proposed Mechanism

The leading hypothesis: a low dose of naltrexone provides brief, transient blockade of opioid receptors (particularly mu and delta receptors). The body compensates for this brief blockade by upregulating endogenous endorphin and enkephalin production. When the naltrexone wears off (its half-life is ~4 hours), the elevated endogenous opioids act on opioid receptors on immune cells, producing immunomodulatory effects.

Proposed downstream effects:

• Reduced microglial activation in the brain (anti-neuroinflammatory)
• Modulation of T-regulatory cell function
• Reduced pro-inflammatory cytokine production
• Possible direct or indirect reduction of mast cell activation (through reduced neuroinflammation and immune modulation)

LDN may also act on Toll-like receptor 4 (TLR4) as an antagonist, which could reduce innate immune activation — a pathway relevant to mast cell activation.

Evidence Status

Honest assessment

LDN has shown promise in small trials and case series for fibromyalgia, Crohn’s disease, multiple sclerosis, and chronic pain. For MCAS specifically, the evidence is almost entirely anecdotal and observational — case reports and patient-reported outcomes. No large, randomized, placebo-controlled trial for MCAS has been published.

Many patients and clinicians report meaningful benefit. The safety profile at low doses is generally favorable (most common side effects: vivid dreams, mild headache, initial sleep disruption — often transient). The cost is low (it’s a generic medication, though typically obtained through compounding pharmacies).

It’s reasonable to consider as part of a multi-intervention approach, with realistic expectations about the evidence level. It is not a first-line or standalone treatment for MCAS.

Practical Notes

Typically taken at bedtime. Dose is usually titrated up from 0.5-1mg to the target dose of 1.5-4.5mg over several weeks. Available from compounding pharmacies. Must be prescribed — not available over the counter.